BridgeBio Pharma, Inc. develops and commercializes medicines for genetic conditions through a decentralized biopharmaceutical model. News for BBIO centers on Attruby/acoramidis, its oral transthyretin stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM), including clinical data from ATTRibute-CM, commercial updates, Brazil marketing authorization under the BEYONTTRA name, and licensing or commercialization arrangements.
Company updates also cover late-stage genetic-disease programs such as encaleret for autosomal dominant hypocalcemia type 1, BBP-418 for limb-girdle muscular dystrophy type 2I/R9, and oral infigratinib for achondroplasia. Recurring financial and corporate items include quarterly results, product revenue trends, capital actions, employee equity inducement grants, investor conference participation, and pipeline regulatory disclosures.
Phoenix Tissue Repair, an affiliate of BridgeBio Pharma (Nasdaq: BBIO), provided updates on its Phase 1/2 study of PTR-01 for recessive dystrophic epidermolysis bullosa (RDEB). The initial cohorts showed that PTR-01 was well tolerated across nine patients, with no serious adverse events reported. Furthermore, a dose-dependent increase in collagen 7 skin deposition was observed. The trial is progressing with a fourth cohort, and results may lead to a six-month open-label study. Dr. Sanuj K. Ravindran has been appointed as the executive chairman, focusing on creating a systemic treatment for RDEB.
BridgeBio Pharma (Nasdaq: BBIO) announced its Q1 2020 financial results, reporting a net loss of $91.9 million, up from $61.2 million in Q1 2019. The company holds $928.4 million in cash and equivalents, ensuring operational stability amid COVID-19 challenges. Clinical trials are ongoing but slowed in enrollment due to the pandemic. BridgeBio aims to file multiple NDAs and INDs later this year. Despite operational hurdles, recent financing raised $550 million, positioning them to progress their pipeline of 20+ drug programs through 2022.
BridgeBio Pharma (Nasdaq: BBIO) will present at the Bank of America Securities 2020 Health Care Conference on May 14, 2020, at 11 AM ET. The presentation will be accessible via a live webcast on the company’s investor page, with a replay available until August 12, 2020. Founded in 2015, BridgeBio focuses on developing transformative medicines for genetic diseases and cancers with genetic drivers. The company boasts a robust pipeline of over 20 development programs, ranging from early discovery to late-stage development.
BridgeBio Pharma (Nasdaq: BBIO) announced the granting of stock options and restricted stock units on May 1, 2020. The compensation committee approved awards for five employees, totaling 39,600 stock options with an exercise price of $28.97 and 18,230 restricted stock units. These awards comply with Nasdaq Listing Rule 5635(c)(4) and are part of the 2019 Inducement Equity Plan established in November 2019. BridgeBio focuses on developing treatments for genetic diseases and has a pipeline of over 20 programs.